JP2010533649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010533649A5 JP2010533649A5 JP2010516276A JP2010516276A JP2010533649A5 JP 2010533649 A5 JP2010533649 A5 JP 2010533649A5 JP 2010516276 A JP2010516276 A JP 2010516276A JP 2010516276 A JP2010516276 A JP 2010516276A JP 2010533649 A5 JP2010533649 A5 JP 2010533649A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- immunogenic composition
- variant
- substitution
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 49
- 238000006467 substitution reaction Methods 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 230000004927 fusion Effects 0.000 claims description 20
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims description 18
- 101001117311 Mus musculus Programmed cell death 1 ligand 2 Proteins 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 11
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 11
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims 30
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 229930182817 methionine Natural products 0.000 claims 7
- -1 Casp-8 Proteins 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000015735 Beta-catenin Human genes 0.000 claims 2
- 108060000903 Beta-catenin Proteins 0.000 claims 2
- 101710113436 GTPase KRas Proteins 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 1
- 101710163573 5-hydroxyisourate hydrolase Proteins 0.000 claims 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical class CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 102100032959 Alpha-actinin-4 Human genes 0.000 claims 1
- 101710115256 Alpha-actinin-4 Proteins 0.000 claims 1
- 101100181128 Arabidopsis thaliana KIN14F gene Proteins 0.000 claims 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims 1
- 102100026548 Caspase-8 Human genes 0.000 claims 1
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 108010072210 Cyclophilin C Proteins 0.000 claims 1
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims 1
- 102000006471 Fucosyltransferases Human genes 0.000 claims 1
- 108010019236 Fucosyltransferases Proteins 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 102100039717 G antigen 1 Human genes 0.000 claims 1
- 102100039788 GTPase NRas Human genes 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 108010036972 HLA-A11 Antigen Proteins 0.000 claims 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 claims 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 1
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 claims 1
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 claims 1
- 101000866749 Homo sapiens Elongation factor 2 Proteins 0.000 claims 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 1
- 101001036406 Homo sapiens Melanoma-associated antigen C1 Proteins 0.000 claims 1
- 101000610208 Homo sapiens Poly(A) polymerase gamma Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 claims 1
- 101000591201 Homo sapiens Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 claims 1
- 101001073409 Homo sapiens Retrotransposon-derived protein PEG10 Proteins 0.000 claims 1
- 101000973629 Homo sapiens Ribosome quality control complex subunit NEMF Proteins 0.000 claims 1
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 claims 1
- 101000847107 Homo sapiens Tetraspanin-8 Proteins 0.000 claims 1
- 101000671653 Homo sapiens U3 small nucleolar RNA-associated protein 14 homolog A Proteins 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 108010052919 Hydroxyethylthiazole kinase Proteins 0.000 claims 1
- 108010027436 Hydroxymethylpyrimidine kinase Proteins 0.000 claims 1
- 108010030506 Integrin alpha6beta4 Proteins 0.000 claims 1
- 102000016200 MART-1 Antigen Human genes 0.000 claims 1
- 108010010995 MART-1 Antigen Proteins 0.000 claims 1
- 102100025136 Macrosialin Human genes 0.000 claims 1
- 102100039447 Melanoma-associated antigen C1 Human genes 0.000 claims 1
- 102000003505 Myosin Human genes 0.000 claims 1
- 108060008487 Myosin Chemical class 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 claims 1
- 102100040153 Poly(A) polymerase gamma Human genes 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 claims 1
- 102100034089 Receptor-type tyrosine-protein phosphatase kappa Human genes 0.000 claims 1
- 102100035844 Retrotransposon-derived protein PEG10 Human genes 0.000 claims 1
- 102100022213 Ribosome quality control complex subunit NEMF Human genes 0.000 claims 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims 1
- 101710143177 Synaptonemal complex protein 1 Proteins 0.000 claims 1
- 102100036234 Synaptonemal complex protein 1 Human genes 0.000 claims 1
- 108700019889 TEL-AML1 fusion Proteins 0.000 claims 1
- 101150031162 TM4SF1 gene Proteins 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 claims 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 claims 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 claims 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 102100040099 U3 small nucleolar RNA-associated protein 14 homolog A Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 claims 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 claims 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 108010020589 trehalose-6-phosphate synthase Proteins 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 101001117316 Mus musculus Programmed cell death 1 ligand 1 Proteins 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 102000048776 human CD274 Human genes 0.000 description 2
- 102000048770 human CD276 Human genes 0.000 description 2
- 102000054189 human CD80 Human genes 0.000 description 2
- 102000049849 human CD86 Human genes 0.000 description 2
- 102000046492 human ICOSLG Human genes 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- BOFUZZAQNVYZFF-UHFFFAOYSA-N 2-(3-chlorophenyl)-3-methylmorpholine Chemical compound CC1NCCOC1C1=CC=CC(Cl)=C1 BOFUZZAQNVYZFF-UHFFFAOYSA-N 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94978507P | 2007-07-13 | 2007-07-13 | |
| PCT/US2008/069819 WO2009029342A2 (en) | 2007-07-13 | 2008-07-11 | B7-dc variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010533649A JP2010533649A (ja) | 2010-10-28 |
| JP2010533649A5 true JP2010533649A5 (https=) | 2011-08-25 |
Family
ID=40346906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010516276A Pending JP2010533649A (ja) | 2007-07-13 | 2008-07-11 | Ｂ７−ｄｃ改変体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8153595B2 (https=) |
| EP (2) | EP2170946A2 (https=) |
| JP (1) | JP2010533649A (https=) |
| CN (1) | CN101784564B (https=) |
| AU (1) | AU2008293885A1 (https=) |
| CA (1) | CA2693707A1 (https=) |
| WO (1) | WO2009029342A2 (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| US7030219B2 (en) * | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| US7432351B1 (en) * | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
| ES2671893T3 (es) | 2004-10-06 | 2018-06-11 | Mayo Foundation For Medical Education And Research | B7-H1 y PD-1 en el tratamiento del carcinoma de células renales |
| US20090215084A1 (en) * | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
| WO2007082144A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and survivin in cancer |
| WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| EP2170946A2 (en) | 2007-07-13 | 2010-04-07 | The Johns Hopkins University | B7-dc variants |
| EP4464384A3 (en) | 2007-08-17 | 2025-01-08 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| US20110020325A1 (en) * | 2008-02-29 | 2011-01-27 | Kwon Eugene D | Methods for reducing granulomatous inflammation |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2010098788A2 (en) * | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| BR112015011118B1 (pt) | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| EP2950814A4 (en) | 2013-01-31 | 2016-06-08 | Univ Jefferson | FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF |
| CN103965363B (zh) * | 2013-02-06 | 2021-01-15 | 上海白泽生物科技有限公司 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
| US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| ES2714708T3 (es) | 2013-10-01 | 2019-05-29 | Mayo Found Medical Education & Res | Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim |
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| CN103923934B (zh) * | 2014-03-22 | 2016-11-02 | 复旦大学 | 一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用 |
| US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
| EP3152235B1 (en) * | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| EP3171896A4 (en) | 2014-07-23 | 2018-03-21 | Mayo Foundation for Medical Education and Research | Targeting dna-pkcs and b7-h1 to treat cancer |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| US10806951B2 (en) * | 2014-09-24 | 2020-10-20 | Salk Institute For Biological Studies | Sonogenic stimulation of cells |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
| EP4706777A2 (en) | 2016-04-15 | 2026-03-11 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| IL262365B2 (en) | 2016-04-15 | 2024-11-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins ICOS ligand variants and uses thereof |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| DE102016217929A1 (de) | 2016-09-20 | 2018-03-22 | Carl Zeiss Smt Gmbh | Projektionsbelichtungsverfahren und Projektionsbelichtungsanlage für die Mikrolithographie |
| CA3040296A1 (en) * | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| JP7312106B2 (ja) | 2016-10-27 | 2023-07-20 | アイオー バイオテック エーピーエス | 新しいｐｄｌ２化合物 |
| JP2020514321A (ja) | 2017-02-01 | 2020-05-21 | モデルナティーエックス， インコーポレイテッド | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
| EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| JP2020511144A (ja) * | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| WO2018195773A1 (en) * | 2017-04-25 | 2018-11-01 | Sun Yat-Sen University | Use of b7-dc mutant in treatement of asthma |
| CN106924718A (zh) * | 2017-04-27 | 2017-07-07 | 中山大学 | B7‑dc突变体在治疗哮喘中的应用 |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| SMT202600062T1 (it) | 2017-10-18 | 2026-03-09 | Alpine Immune Sciences Inc | Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2020113141A2 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| JP7748393B2 (ja) | 2020-05-08 | 2025-10-02 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
| CN114437189A (zh) * | 2020-10-20 | 2022-05-06 | 中国农业科学院作物科学研究所 | 玉米ZmSmk501蛋白突变体、基因突变体及其分子标记和应用 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4272398A (en) * | 1978-08-17 | 1981-06-09 | The United States Of America As Represented By The Secretary Of Agriculture | Microencapsulation process |
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US5155020A (en) | 1989-03-08 | 1992-10-13 | Health Research Inc. | Recombinant poxvirus host range selection system |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4650764A (en) * | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4861719A (en) * | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| EP0545913B1 (en) * | 1986-08-18 | 1999-02-24 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
| US4980289A (en) * | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| US4861627A (en) | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
| US5750375A (en) * | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
| DE68926888T2 (de) * | 1988-01-22 | 1997-01-09 | Zymogenetics Inc | Verfahren zur Herstellung von sekretierten Rezeptoranalogen |
| US6018026A (en) * | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US5278056A (en) * | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| US5175099A (en) * | 1989-05-17 | 1992-12-29 | Research Corporation Technologies, Inc. | Retrovirus-mediated secretion of recombinant products |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5204243A (en) | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
| US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1992000092A1 (en) | 1990-07-02 | 1992-01-09 | Bristol-Myers Squibb Company | Ligand for cd28 receptor on b cells and methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| AU643141B2 (en) | 1991-03-15 | 1993-11-04 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| KR0163798B1 (ko) | 1991-07-03 | 1999-01-15 | 나가따 마사오 | 열가성 폴리우레탄 탄성체, 그의 제조 방법, 그의 제조 장치 및 그로부터 제조한 탄성 섬유 |
| US5942607A (en) * | 1993-07-26 | 1999-08-24 | Dana-Farber Cancer Institute | B7-2: a CTLA4/CD28 ligand |
| US5861310A (en) * | 1993-11-03 | 1999-01-19 | Dana-Farber Cancer Institute | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
| WO1995005464A1 (en) | 1993-08-16 | 1995-02-23 | Arch Development Corporation | B7-2: ctla4/cd28 counter receptor |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US5675848A (en) | 1995-10-18 | 1997-10-14 | Mallinckrodt Medical, Inc. | Inflatable blanket having perforations of different sizes |
| US20030171551A1 (en) | 1997-01-31 | 2003-09-11 | Joseph D. Rosenblatt | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
| US7411051B2 (en) | 1997-03-07 | 2008-08-12 | Human Genome Sciences, Inc. | Antibodies to HDPPA04 polypeptide |
| US7368531B2 (en) * | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US20070224663A1 (en) | 1997-03-07 | 2007-09-27 | Human Genome Sciences, Inc. | Human Secreted Proteins |
| US20060223088A1 (en) | 1997-03-07 | 2006-10-05 | Rosen Craig A | Human secreted proteins |
| EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CN1688695B (zh) * | 2000-04-28 | 2011-05-11 | 约翰霍普金斯大学 | 新的树突状细胞共刺激分子 |
| US7030219B2 (en) * | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| US20030031675A1 (en) * | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| CA2412377A1 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| JP2004501631A (ja) | 2000-06-28 | 2004-01-22 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用 |
| CA2406649A1 (en) | 2000-06-30 | 2002-01-10 | Human Genome Sciences, Inc. | B7-like polynucleotides, polypeptides, and antibodies |
| US6635750B1 (en) * | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
| US20020107363A1 (en) * | 2000-09-20 | 2002-08-08 | Amgen, Inc. | B7-Like molecules and uses thereof |
| US6743619B1 (en) | 2001-01-30 | 2004-06-01 | Nuvelo | Nucleic acids and polypeptides |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| US20060084794A1 (en) | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ES2302845T3 (es) | 2001-10-19 | 2008-08-01 | Zymogenetics, Inc. | Factor de crecimiento dimerizado y materiales y metodos para producirlo. |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| US7164500B2 (en) | 2002-01-29 | 2007-01-16 | Hewlett-Packard Development Company, L.P. | Method and apparatus for the automatic generation of image capture device control marks |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| US7432351B1 (en) * | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| ATE517914T1 (de) | 2004-03-08 | 2011-08-15 | Zymogenetics Inc | Dimere fusionsproteine und materialien und verfahren zu deren herstellung |
| AU2005302459A1 (en) | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| CN101355965A (zh) | 2005-06-08 | 2009-01-28 | 达纳－法伯癌症研究院 | 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物 |
| US20070231344A1 (en) * | 2005-10-28 | 2007-10-04 | The Brigham And Women's Hospital, Inc. | Conjugate vaccines for non-proteinaceous antigens |
| WO2008037080A1 (en) | 2006-09-29 | 2008-04-03 | Universite De Montreal | Methods and compositions for immune response modulation and uses thereof |
| CN103536915A (zh) | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| EP2170946A2 (en) | 2007-07-13 | 2010-04-07 | The Johns Hopkins University | B7-dc variants |
| EP2578677A1 (en) | 2007-08-09 | 2013-04-10 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
| WO2009114110A1 (en) | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
-
2008
- 2008-07-11 EP EP08828784A patent/EP2170946A2/en not_active Withdrawn
- 2008-07-11 CA CA2693707A patent/CA2693707A1/en not_active Abandoned
- 2008-07-11 EP EP12172947.9A patent/EP2514762B1/en not_active Ceased
- 2008-07-11 US US12/171,802 patent/US8153595B2/en active Active
- 2008-07-11 WO PCT/US2008/069819 patent/WO2009029342A2/en not_active Ceased
- 2008-07-11 JP JP2010516276A patent/JP2010533649A/ja active Pending
- 2008-07-11 AU AU2008293885A patent/AU2008293885A1/en not_active Abandoned
- 2008-07-11 CN CN200880024511.XA patent/CN101784564B/zh active Active
-
2012
- 2012-03-07 US US13/413,990 patent/US8445447B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010533649A5 (https=) | ||
| JP2012500652A5 (https=) | ||
| US11806365B2 (en) | Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis | |
| US20180273640A1 (en) | Modified t lymphocytes having improved specificity | |
| US11130820B2 (en) | Chimeric antigen receptors | |
| ES2973524T3 (es) | Métodos para mejorar la eficacia de la transducción de vectores en los linfocitos T | |
| EP2662383A1 (en) | PD-I antagonists and methods for treating infectious disease | |
| CN101784564B (zh) | B7-dc变体 | |
| CN105163724A (zh) | 包含囊泡的药物组合物 | |
| JP2020516601A5 (https=) | ||
| JP2018528191A5 (https=) | ||
| CN120350015A (zh) | 靶向检查点分子的dna单克隆抗体 | |
| Khan et al. | Clinical development of intramuscular electroporation: providing a “boost” for DNA vaccines | |
| ES2929771T3 (es) | Proceso para fabricación de células T mejorado | |
| WO2017003305A1 (en) | Peptides and uses thereof | |
| Jones | Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection. | |
| NZ712373B2 (en) | Modified t lymphocytes | |
| NZ751539B2 (en) | Modified t lymphocytes |